Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX) will announce its fourth quarter and full year 2021 financial results on February 28, 2022, at 4:30 p.m. ET. The announcement will include recent corporate updates. Investors can participate in a live webcast or dial in to listen. Mirati focuses on breakthrough therapies for cancer, with drugs like adagrasib (MRTX849) and sitravatinib under development. The company emphasizes its dedication to addressing unmet needs in oncology, especially lung cancer, while managing inherent risks in drug development.
- Upcoming financial results announcement may provide insights into company performance.
- Active development of breakthrough cancer therapies like adagrasib and sitravatinib.
- None.
SAN DIEGO, Feb. 14, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the fourth quarter and full year of 2021 along with recent corporate updates on February 28, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on February 28, company executives will provide company updates and review financial results.
Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 313-209-4906 or international +1 877-502-9276, confirmation code: 6820152. A replay of the call will be available approximately 2 hours after the event has ended at the same website or by dialing in the U.S. toll free 1+ 719-457-0820 or international +1 888-203-1112, confirmation code: 6820152.
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.
For more information about Mirati Therapeutics Inc., visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati"). Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati's drug development pipeline, including without limitation adagrasib (MRTX849), sitravatinib, MRTX1719 and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.
Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the "SEC") available at the SEC's Internet site (www.sec.gov).These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Mirati Contacts
Investor Relations: Temre Johnson | 858-332-3562 | ir@mirati.com
Media Relations: Priyanka Shah | 908-447-6134 | media@mirati.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-to-report-fourth-quarter-and-full-year-financial-results-for-2021-and-recent-corporate-updates-on-february-28-2022-301481166.html
SOURCE Mirati Therapeutics, Inc.
FAQ
What is the date for Mirati Therapeutics' financial results announcement?
What financial results will Mirati Therapeutics report?
How can I listen to the Mirati Therapeutics financial results call?
What is Mirati's focus in drug development?
What drugs are being developed by Mirati Therapeutics?
